Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.47 |
| ▸ | MELK | Q14680 | 2/20 | 0.47 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.47 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903400 | 0.87 | GRM5 (0.40) | NPC1RAB9AGBA1SMN1; SMN2POLB | |
| SCHEMBL4907684 | 0.84 | GRM5 (0.49) | NPC1RAB9AGBA1PIM1SMN1; SMN2 | |
| SCHEMBL4908858 | 0.83 | NPC1 (0.43) | NPC1RAB9AGBA1DAPK3PIM1 | |
| SCHEMBL4906741 | 0.83 | PIK3CA (0.45) | NPC1RAB9AGBA1GRM5 | |
| SCHEMBL4903459 | 0.81 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2KMT2AABCG2 | |
| SCHEMBL4909014 | 0.79 | CSNK2A1 (0.45) | NPC1RAB9ASMN1; SMN2GRM5CSNK2A1 | |
| SCHEMBL5204946 | 0.78 | PDE10A (0.52) | NPC1RAB9AGBA1SMN1; SMN2POLB | |
| SCHEMBL4906651 | 0.77 | AURKA (0.41) | NPC1RAB9ADAPK3PRKD3PIM1 | |
| SCHEMBL4908197 | 0.77 | GRM5 (0.68) | NPC1RAB9AKMT2AGRM5LMNA | |
| SCHEMBL7460408 | 0.76 | PDE10A (0.62) | DAPK3PRKD3PIM1CDK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101133027-B | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE | 2011-03-30 | — | — | CN | claimed |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2008-10-30 | — | — | US | claimed |
| US-7414060-B2 | Pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | claimed |
| CN-101133027-A | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | CN | claimed |
| EP-1858854-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | claimed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | claimed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | claimed |
| EP-1858854-B1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-05-07 | — | — | EP | disclosed |
| CN-101133027-B | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE | 2011-03-30 | — | — | CN | disclosed |
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | JAESCHKE GEORG | 2008-10-30 | — | — | US | disclosed |
| US-7414060-B2 | Pyridine-2-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-08-19 | — | — | US | disclosed |
| CN-101133027-A | Pyridine-2-carboxamide derivatives as mglur5 antagonists | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | CN | disclosed |
| EP-1858854-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094639-A1 | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | HOFFMANN-LA ROCHE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269256-A1 | PYRIDINE-2-CARBOXYAMIDE DERIVATIVES | CNR2, CNR1, CHRNA2 | NPC1 1444/4885RAB9A 1897/4885GBA1 732/4885 |
| US-20060199960-A1 | e.g. 6-Methyl-3-(pyridin-3-ylamino)-pyridine-2-carboxylic acid (4-methyl-thiazol-2-yl)-amide; metabotropic glutamate receptor antagonists (mGluR); central nervous system disorders, antidepressant, anxiolytc agent; psychosis, epilepsy, schizophrenia, Alzheimer's disease, cognitive disorders | GRM3, GRM2, GRM1 | NPC1 911/4885RAB9A 1868/4885GBA1 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.